Physician profile
Hamza Khalid
NPI 1063667608
$9,767.30
in general payments reported to CMS, 2019-2025
42 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $161 · 2021: $798 · 2022: $1,890 · 2023: $2,141 · 2024: $2,313 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,191.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,664.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,110.73 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $823.06 | 2021-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $636.78 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $443.59 | 2021-2025 | Entyvio, Eohilia |
| Abbott Laboratories | $282.84 | 2021-2024 | Proclaim |
| Genzyme Corporation | $247.71 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $226.77 | 2024-2025 | Voquezna |
| Ethicon US, LLC | $219.12 | 2022-2023 | Linx Reflux Management System |
| Ardelyx, INC. | $191.03 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $181.82 | 2024-2025 | Endoflip, Nexpowder, Eleview |
| Allergan, INC. | $176.56 | 2019-2020 | |
| Celgene Corporation | $171.30 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $169.64 | 2020-2023 | Linzess |
| Pfizer INC. | $150.48 | 2019-2025 |
Show all 39 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.